A variety of innovations, such as techniques for early detection of Epstein-Barr (EBV) and CMV infections, bone marrow augmentation, the adjunct use of the interleukin-# antagonist daclizumab, lower initial tacrolimus doses with target trough levels of # to # ng/ml, and most recently allograft irradiation were considered to have contributed to improved results in this indication over time (Abu-Elmagd et al., Ann Surg
Seuraa tuota poliisiautoa!EMEA0.3 EMEA0.3